senario16 Jun 2019 23:11
Just maybe, they have been talking to a big pharmaceutical all along, like they say they have. Big maybe, the big pharma do not want big institutions investing , that is why they have "no skin in the game" They now that dilution is required. But they will not sell before end of phase 2 trial data, where it will give investors value for money. Just like any other scenario on this board.